Contents of plasma М2-pyruvate kinase (M2-РК) in patients with inflammatory bowel diseases
Abstract
Aim of investigation. Assessment of М2-pyruvate kinase level (M2-РК) at patients with ulcerative colitis (UC) and Crohn’s disease (CD) and its relation to course, clinical and endoscopical activity of disease.
Material and methods. Overall 70 patients were investigated: 42 – with UC, 15 – with CD, 13 – with irritable bowel syndrome (IBS) and 10 healthy patients. Blood plasma concentration of M2-РК was determined by solid-phase sandwich method of enzyme-linked immunoassay with application of «ScheBo» (Germany) test-systems.
Results. The level of M2-РК in patients with UC, CD, IBS and healthy persons was 29,1±3,0, 17,3±1,5, 7,9±1,6 and 7,0±1,5 U/ml respectively (р<0,05 – for UC and CD in comparison to IBS and control group and for UC in comparison to CD). The level of M2-РК considerably raised in patients with severe (45,9±6,4 U/ml) and moderate (20,9±3,2 U/ml) UC, including steroid-resistant patients (61,5±6,2 U/ml), in comparison to patients in remission (11,0±1,8 U/ml, р><0,05) and at patients with chronic continuous course in comparison to chronic relapsing course (40,3±5,0 and 22,7±3,8 U/ml, р><0,05). The level of M2-РК had the strong tendency to increase with progression of endoscopic activity of UC. Increase of M2-РК concentration (М±σ of the control group, р><0,05) was observed in 76,2% of UC patients, at 73,3% of patients with CD and in 15,4% of patients with IBS.>< 0,05 – for UC and CD in comparison to IBS and control group and for UC in comparison to CD). The level of M2-РК considerably raised in patients with severe (45,9±6,4 U/ml) and moderate (20,9±3,2 U/ml) UC, including steroid-resistant patients (61,5±6,2 U/ml), in comparison to patients in remission (11,0±1,8 U/ml, р<0,05) and at patients with chronic continuous course in comparison to chronic relapsing course (40,3±5,0 and 22,7±3,8 U/ml, р><0,05). The level of M2-РК had the strong tendency to increase with progression of endoscopic activity of UC. Increase of M2-РК concentration (М±σ of the control group, р><0,05) was observed in 76,2% of UC patients, at 73,3% of patients with CD and in 15,4% of patients with IBS.>< 0,05) and at patients with chronic continuous course in comparison to chronic relapsing course (40,3±5,0 and 22,7±3,8 U/ml, р< 0,05). The level of M2-РК had the strong tendency to increase with progression of endoscopic activity of UC. Increase of M2-РК concentration (М±σ of the control group, р<0,05) was observed in 76,2% of UC patients, at 73,3% of patients with CD and in 15,4% of patients with IBS.>< 0,05) was observed in 76,2% of UC patients, at 73,3% of patients with CD and in 15,4% of patients with IBS.
Conclusions. Blood level of M2-РК of patients with UC and CD increases considerably. Elevation of M2-РК level at patients with UC is associated to enhancement of clinical and endoscopical activity, chronic continuous course and steroid-resistance.
About the Authors
Ye. A. Konovich
Государственный научный центр колопроктологии Росмедтехнологий
Russian Federation
Russian Federation
I. L. Khalif
Государственный научный центр колопроктологии Росмедтехнологий
Russian Federation
Russian Federation
References
1. Михайлова Т.Л., Халиф И.Л. Язвенный колит. Болезнь Крона. Клиническая характеристика // Неспецифические воспалительные заболевания кишечника / Под ред. Г.И. Воробьева, И.Л. Халифа.– М.: Миклош, 2008. – C. 136–155.
2. Сергеева Н.С., Мишунина М.П., Хомяков В.М. и др. Динамика содержания в плазме крови опухолевой пируваткиназы М2-типа (TuM2-PK) на этапах диагностики, лечения и мониторинга больных колоректальным раком // Рос. онкол. журн. – 2007. – № 5. – C. 9–12.
3. Cerwenca H., Aigner R., Bacher H. et al. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions // Anticancer Res. – 1999. – Vol. 19. – P.849–852.
4. Chung-Faye G., Hayee B., Maestranzi S. et al. Fecal M2-pyruvate kinase (M2-PK): a novel marker of intestinal inflammation // Inflamm. Bowel Dis. – 2007. – Vol. 13.– P. 1374–1378.
5. Czub E., Herzig K.H., Szaflarska-Popawska A. et al. Fecal pyruvate kinase:a potential new marker for intestinal inflammation in chidren with inflammatory bowel disease // Scand. J. Gastroenterol. – 2007. – Vol. 42, N 10. – P. 1147–1150.
6. Eigenbrodt E., Reinacher M., Scheefers-Borchel U. et al. Double role for pyruvate kinase type M2 in the expansion of phosphometabolite pools found in tumor cells // Critical Rev. Oncogenesis. – 1992. – Vol. 3. – P. 91–115.
7. Ewald T., Toepler M., Akinci A. et al. Pyruvate kinase M2 (tumor M2-PK) as a screening tool for colorectal cancer (CRC). A review of current published data // Z.Gastroenterol. – 2005. – Vol. 43, N 12. – P. 1313–1317.
8. Hang U., Hundt S., Brenner H. Sensitivity and specificity of faecal tumour M2-pyruvate kinase for detection of colorectal adenomas in a large screening study // Br. J. Cancer. – 2008. – Vol. 99, N 1. – P. 133–135.
9. Ibsen K.H., Orlando R.A., Garrat K.N. et al. Expression of multimolecular forms of pyruvate kinase in normal, benign and malignant human breast tissue // Cancer Res. – 1982. – Vol. 42. – P. 888–892.
10. Izcue A., Coombes J.L., Powrie F. Regulatory lymphocytes and intestinal Inflammation // Annu. Rev. Immunol. – 2009. – Vol. 27. – P. 313–338.
11. Jeffery J., Lewis S.J., Ayling R.M. Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders// Inflamm. Bowel Dis. – 2009. – Vol. 15, N 11. – P. 1630–1634.
12. Johnson M.W., Maestranzi S., Duffy A.M. et al. Faecal M2-pyruvate kinase: a novel noninvasive marker of ileal pouch inflammation // Eur. J. Gastroenterol. Hepatol. – 2009. – Vol. 21, N 5. – P. 544–550.
13. Kobayashi T., Okamoto S., Hisamatsu T. et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn′s disease // Gut. – 2008. – Vol. 57. – P. 1682–1689.
14. Luftner D., Mesterharm J., Akrivakis C. et al. Tumor Type M2-pyruvate kinase expression in advanced breast cancer // Anticancer Res. – 2000. – Vol. 20. – P. 5077–5082.
15. Mazurek S., Grimm H., Oehmke M. et al. Tumor M2PK and glutaminolytiс enzymes in the metabolic shift of tumor cells // Anticancer Res. – 2000. – Vol. 20. – P. 5151–5154.
16. Oremek G., Muller R., Sapoutzis N., Wigand R. Pyruvate kinase type tumor M2 plasma levels in patients afflicted with rheumatic diseases // Anticancer Res. – 2003. – Vol. 23. – P. 1131–1134.
17. Oremek G., Rutner F., Sapoutzis N., Sauer-Eppel H. Tumor marker pyruvate kinase type tumor M2 in patients suffering from diabetic nephropathy // Anticancer Res. – 2003. – Vol. 23. – P. 1155–1158.
18. Oremek G., Sapoutzis N., Kramer W. et al. Value of tumor M2 (Tu M2-PK) in patients with renal carcinoma // Anticancer Res. – 2000. – Vol. 20. – P. 5095– 5098.
19. Rakoff-Nahoum S., Hao L., Medzhitov R. Role of toll-like receptors in spontaneous commensal-dependent colitis // Immunity. – 2006. – Vol. 25. – P. 319–329.
20. Schneider J., Morr H., Velcovsky H. et al. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases // Cancer Detect. Prev. – 2000. – Vol. 24, N 6. – P. 531–535.
21. Schneider J., Velcovsky H., Morr H. et al. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 211, NCE and SCC in the diagnosis of lung cancer // Anticancer Res. – 2000. – Vol. 20. – P. 5053–5058.
22. Shih D.Q., Targan S.R. Immunopathogenesis of inflammatory bowel disease // World J. Gastroenterol. – 2008. – Vol. 14. – P. 390–400.
23. Staib P., Hoffmann M., Schinkothe T. Plasma levels of tumor M2-pyruvate kinase should not be used as a tumor marker for hematological malignancies and solid tumors // Clin. Chem. Lab. Med. – 2006. – Vol. 44, N 1. – P. 28–31.
24. Strober W., Fuss I., Mannon P. The fundamental basis of inflammatory bowel disease // J. Clin. Invest. – 2007. – Vol. 117. – P. 514–521.
25. Walkowiak J., Banasiewicz T., Krokowicz P. et al. Fecal pyruvate kinase (M2-PK): a new predictor for inflammation and severity of pouchitis // Scand. J. Gastroenterol. – 2005. – Vol. 40, N 12. – P. 1493–1494.
26. Zenewicz L.A., Antov A., Flawell R.A. CD4 T-cell differentiation and Inflammatory bowel disease // Trends Mol. Med. – 2009. – Vol. 15. – P. 199–207.
Review
For citations:
Konovich Ye.A., Khalif I.L. Contents of plasma М2-pyruvate kinase (M2-РК) in patients with inflammatory bowel diseases. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2010;20(5):75-79. (In Russ.)
Views:
54
Email this article 
